Overbrook Management Corp Invests $9.61 Million in AbbVie Inc. $ABBV

Overbrook Management Corp bought a new stake in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, Holdings Channel reports. The firm bought 42,059 shares of the company’s stock, valued at approximately $9,610,000. AbbVie accounts for about 1.7% of Overbrook Management Corp’s investment portfolio, making the stock its 21st largest holding.

A number of other large investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new position in AbbVie in the 2nd quarter valued at $26,000. Chelsea Counsel Co. bought a new position in AbbVie during the 3rd quarter worth $26,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie during the 3rd quarter worth $31,000. Caitlin John LLC acquired a new stake in shares of AbbVie during the third quarter worth $33,000. Finally, Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie during the second quarter worth $39,000. Institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company’s stock.

AbbVie Stock Down 0.1%

ABBV stock opened at $204.89 on Tuesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The business has a 50-day simple moving average of $222.79 and a 200 day simple moving average of $224.80. The company has a market cap of $362.29 billion, a PE ratio of 86.82, a price-to-earnings-growth ratio of 0.71 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the company posted $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analysts Set New Price Targets

Several research firms recently commented on ABBV. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Barclays initiated coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective for the company. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 4th. Morgan Stanley raised their target price on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.